MLAB
Mesa Laboratories, Inc. NASDAQ Listed Feb 29, 1984$95.10
+0.16%
vs $94.95
Mkt Cap $516.3M
52w Low $57.44
72.9% of range
52w High $109.13
50d MA $101.99
200d MA $84.97
P/E (TTM)
-264.2x
EV/EBITDA
13.4x
P/B
3.2x
Debt/Equity
1.1x
ROE
1.8%
P/FCF
12.2x
RSI (14)
40.50
ATR (14)
$5.43
Beta
0.89
50d MA
$101.99
200d MA
$84.97
Avg Volume
216.8K
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
12100 West Sixth Avenue · Lakewood, CO 80228 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27, 2026 | BMO | 2.09 | 3.30 | +57.9% | 106.17 | -0.9% | -14.5% | +13.5% | -1.0% | +3.2% | +1.3% | — |
| Feb 3, 2026 | BMO | 1.40 | 3.07 | +119.3% | 87.53 | +1.8% | +4.6% | -0.4% | +2.3% | -2.6% | +1.3% | — |
| Nov 6, 2025 | BMO | 1.56 | 1.76 | +12.8% | 74.87 | +1.3% | +1.5% | +7.7% | -2.2% | -0.2% | -5.1% | — |
| Aug 5, 2025 | BMO | 2.46 | 2.32 | -5.7% | 57.44 | +0.6% | +8.0% | +2.4% | +1.3% | -5.9% | +4.6% | — |
| May 28, 2025 | BMO | 2.75 | 2.23 | -18.9% | 103.07 | +0.7% | +1.5% | -3.8% | -2.6% | +2.2% | +0.8% | — |
| Feb 4, 2025 | BMO | 1.41 | 2.67 | +89.4% | 137.27 | +1.4% | +1.2% | +2.0% | +4.3% | +4.7% | -2.8% | — |
| Nov 7, 2024 | BMO | 2.48 | 2.45 | -1.2% | 117.89 | +0.1% | +0.8% | +0.1% | -5.5% | -4.1% | -2.9% | — |
| Aug 5, 2024 | BMO | 2.33 | 2.83 | +21.5% | 104.71 | +2.7% | +8.0% | +5.2% | +7.8% | -6.8% | -2.0% | — |
| Jun 5, 2024 | BMO | -0.11 | 2.77 | +2618.2% | 107.20 | -1.0% | +0.1% | -2.4% | -4.6% | -4.4% | -0.2% | — |
| Feb 5, 2024 | BMO | 2.04 | 2.02 | -1.0% | 99.30 | -0.2% | -3.4% | -5.5% | +3.1% | +0.5% | +1.6% | — |
| Nov 6, 2023 | BMO | 1.65 | 1.91 | +15.8% | 91.91 | -1.9% | +1.5% | +0.4% | -8.6% | -0.7% | -0.6% | — |
| Aug 3, 2023 | BMO | 1.67 | 1.77 | +6.0% | 132.64 | -0.6% | +2.6% | +0.4% | +1.7% | -0.9% | +1.3% | — |
| May 25, 2023 | AMC | 1.98 | 1.94 | -2.0% | 141.06 | -0.8% | -0.3% | -5.6% | -2.5% | -1.0% | +2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $87.53 | $89.07 | +1.8% | +4.6% | -0.4% | +2.3% | -2.6% | +1.3% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $77.77 | $78.48 | +0.9% | +0.1% | +1.0% | +1.4% | +1.0% | +0.5% |
| Aug 8 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $63.47 | $63.28 | -0.3% | +1.3% | -5.9% | +4.6% | +9.5% | -2.0% |
| May 30 | Wells Fargo | Maintains | Underweight → Underweight | — | $104.64 | $102.75 | -1.8% | -3.8% | -2.6% | +2.2% | +0.8% | -1.1% |
| Oct 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $129.86 | $129.34 | -0.4% | +0.4% | +1.5% | -1.3% | +2.2% | -5.0% |
| Aug 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $104.71 | $107.50 | +2.7% | +8.0% | +5.2% | +7.8% | -6.8% | -2.0% |
| Jul 2 | Evercore ISI | Maintains | Outperform → Outperform | — | $88.45 | $87.54 | -1.0% | -0.8% | +3.1% | +1.2% | +4.0% | -2.5% |
| Apr 4 | Evercore ISI | Maintains | Outperform → Outperform | — | $99.80 | $102.17 | +2.4% | +0.4% | +0.8% | +5.2% | +0.7% | -2.7% |
| Jan 4 | Evercore ISI | Upgrade | In Line → Outperform | — | $97.13 | $99.00 | +1.9% | +3.6% | -1.7% | +3.7% | -0.5% | -2.2% |
| Jan 4 | Evercore ISI | Downgrade | Outperform → In Line | — | $286.64 | $285.12 | -0.5% | -2.6% | +0.6% | +3.0% | +0.8% | -0.7% |
| Nov 10 | KeyBanc | Maintains | Sector Weight → Equal Weight | — | $267.12 | $271.11 | +1.5% | +2.4% | -0.5% | +0.5% | +2.6% | +3.2% |
| Nov 10 | KeyBanc Capital Markets | Maintains | Sector Weight → Equal Weight | — | $267.12 | $271.11 | +1.5% | +2.4% | -0.5% | +0.5% | +2.6% | +3.2% |
| Oct 2 | JP Morgan | Maintains | Neutral → Neutral | — | $258.40 | $254.68 | -1.4% | +0.2% | +0.6% | +2.1% | +2.8% | +1.6% |
| Dec 4 | Jefferies | Maintains | Buy → Buy | — | $232.46 | $235.80 | +1.4% | +5.5% | +2.0% | -0.9% | -1.5% | -0.5% |
| Aug 26 | Evercore ISI | Maintains | Outperform → Outperform | — | $206.69 | $212.85 | +3.0% | +3.4% | +0.0% | +1.2% | +1.2% | +1.1% |
| Jun 10 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $130.55 | $126.49 | -3.1% | -6.2% | -0.7% | +0.2% | +1.1% | +0.1% |
| Feb 10 | Janney Capital | Maintains | Buy → Buy | — | $78.14 | $80.15 | +2.6% | +3.0% | -0.1% | +2.5% | +2.0% | +6.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Sakys JohnOff | CFO | Sell | 1,223 | $101.27 | $124K | 16,538 | +0.16% | — |
| Jun 16, 2026 | Crennen Lyndsey ElizabethOff | CAO | Sell | 118 | $101.27 | $12K | 1,473 | +0.16% | — |
| Jun 16, 2026 | Archbold Brian DavidOff | SVP Operations | Sell | 1,151 | $101.27 | $117K | 3,710 | +0.16% | — |
8-K · 2.02
!! High
Mesa Laboratories, Inc. -- 8-K 2.02: Earnings Results
Mesa Laboratories reported financial results for Q4 and fiscal year 2026, providing investors with updated performance metrics to evaluate the company's operational and financial health.
May 27
8-K
Unknown — 8-K Filing
A board member's departure without operational disagreement suggests routine leadership transition, reducing governance risk concerns but potentially signaling planned strategic shifts investors should monitor.
Mar 23
8-K · 5.02
!!! Very High
Mesa Laboratories Inc -- 8-K 5.02: Executive Change
Mesa Laboratories appoints Dr. Siddhartha Kadia as President following Owens' resignation, signaling leadership transition that investors should monitor for strategic direction changes.
Mar 9
8-K
Mesa Laboratories Inc -- 8-K Filing
Mesa Laboratories reported third quarter fiscal 2026 results ending December 31, 2025, demonstrating operational performance for the life science tools and quality control solutions provider.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 351,178 | $28M | Reduced | Dec 2025 |
| 2 | Boston Partners | 268,711 | $24M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 232,643 | $21M | New | Mar 2026 |
| 4 | Select Equity Group, L.p. | 206,435 | $16M | Added | Dec 2025 |
| 5 | Aqr Capital Management Llc | 170,562 | $15M | Added | Mar 2026 |
| 6 | Russell Investments Group, Ltd. | 135,069 | $12M | Added | Mar 2026 |
| 7 | Diamond Hill Capital Management Inc | 141,973 | $11M | Added | Dec 2025 |
| 8 | Raymond James Financial Inc | 122,911 | $11M | Added | Mar 2026 |
| 9 | Roubaix Capital, Llc | 72,115 | $6M | Added | Mar 2026 |
| 10 | Janus Henderson Group Plc | 69,401 | $6M | New | Mar 2026 |
| 11 | Northern Trust Corp | 69,264 | $6M | Added | Mar 2026 |
| 12 | Meros Investment Management, Lp | 68,032 | $6M | Reduced | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 57,871 | $5M | Added | Mar 2026 |
| 14 | D.e. Shaw & Co | 54,558 | $5M | Reduced | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 52,586 | $5M | New | Mar 2026 |
| 16 | Wasatch Advisors Lp | 51,233 | $5M | New | Mar 2026 |
| 17 | Jane Street Group, Llc | 56,371 | $4M | Added | Dec 2025 |
| 18 | Bank Of New York Mellon Corp | 43,937 | $4M | Reduced | Mar 2026 |
| 19 | Monimus Capital Management, Lp | 40,842 | $3M | Added | Dec 2025 |
| 20 | Renaissance Technologies Llc | 31,600 | $3M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$516.3M
Enterprise Value
$565.9M
P/E (TTM)
-264.17x
Forward P/E
11.17x
PEG Ratio
3.29x
P/B
3.23x
P/S
2.14x
P/FCF
12.20x
EV/EBITDA
13.36x
Shares Out
5.4M
Financials (TTM)
Revenue
$241.0M
Net Income
-$2.0M
EBITDA
$42.3M
Free Cash Flow
$42.3M
Op Cash Flow
$46.8M
EPS Basic
$-0.36
EPS Diluted
$-0.36
EPS Forward
$8.52
Gross Margin
62.6%
Op Margin
6.8%
Net Margin
-0.8%
Balance Sheet
Total Assets
$433.3M
Total Liab.
$273.5M
Total Equity
$159.8M
Cash
$27.3M
LT Debt
$76.9M
Book Value/Sh
$29.44
Debt/Equity
1.14x
Current Ratio
0.63
Quick Ratio
0.47
Returns & Growth
ROE
1.8%
ROA
0.8%
ROIC
-1.5%
Rev Growth YoY
+11.5%
EPS Growth YoY
+99.2%
Price Returns
2W
+1.5%
1M
+2.0%
3M
+5.6%
6M
+27.2%
12M
+1.4%
Technicals
52W High
$109.13
52W Low
$57.44
50d MA
$101.99
200d MA
$84.97
RSI (14)
40.50
ATR (14)
$5.43
Beta
0.89
Avg Volume
217K
Dividends
Div Rate
$0.64
Div Yield
0.6%
Frequency
4
Ex-Div Date
May 29, 2026
Analyst Price Targets
Consensus
$94.00
High
$94.00
Low
$94.00
Median
$94.00
Data updated apr 26, 2026 12:30pm
· Source: financialmodelingprep.com